Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review
Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …
[HTML][HTML] The emerging role of cell-free DNA as a molecular marker for cancer management
AJ Bronkhorst, V Ungerer, S Holdenrieder - Biomolecular detection and …, 2019 - Elsevier
An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
[PDF][PDF] Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is among the leading causes of worldwide cancer‐related
morbidity and mortality. Poor prognosis of HCC is attributed primarily to tumor presentation …
morbidity and mortality. Poor prognosis of HCC is attributed primarily to tumor presentation …
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
M Garcia-Pardo, M Makarem, JJN Li, D Kelly… - British Journal of …, 2022 - nature.com
In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …
revolutionised the management of patients with solid tumours. Recent advances in the …
Heterogeneity in colorectal cancer: a challenge for personalized medicine?
C Molinari, G Marisi, A Passardi, L Matteucci… - International journal of …, 2018 - mdpi.com
High inter-patient variability and high spatial heterogeneity are features of colorectal cancer
(CRC). This may influence the molecular characterization of tumor tissue, now mandatory for …
(CRC). This may influence the molecular characterization of tumor tissue, now mandatory for …
[HTML][HTML] ctDNA and CTCs in liquid biopsy–current status and where we need to progress
MHD Neumann, S Bender, T Krahn… - Computational and …, 2018 - Elsevier
We discuss the current status of liquid biopsy and its advantages and challenges with a
focus on pre-analytical sample handling, technologies and workflows. The potential of …
focus on pre-analytical sample handling, technologies and workflows. The potential of …
S3-leitlinie–kolorektales karzinom
W Schmiegel, B Buchberger… - Zeitschrift für …, 2017 - thieme-connect.com
2.1 Geltungsbereich und Zweck 2.1. 1. Zielsetzung und Fragestellung Das Kolorektale
Karzinom (KRK) ist mit etwa 64 000 Neuerkrankungen und ca. 26 000 Todesfällen pro Jahr …
Karzinom (KRK) ist mit etwa 64 000 Neuerkrankungen und ca. 26 000 Todesfällen pro Jahr …
Potential utility of liquid biopsy as a diagnostic and prognostic tool for the assessment of solid tumors: implications in the precision oncology
Liquid biopsy is a technique that utilizes circulating biomarkers in the body fluids of cancer
patients to provide information regarding the genetic landscape of the cancer. It is emerging …
patients to provide information regarding the genetic landscape of the cancer. It is emerging …
[HTML][HTML] Concordance of blood-and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
J Grasselli, E Elez, G Caratù, J Matito, C Santos… - Annals of …, 2017 - Elsevier
ABSTRACT Background Circulating tumor DNA (ctDNA) is a potential source for tumor
genome analysis. We explored the concordance between the mutational status of RAS in …
genome analysis. We explored the concordance between the mutational status of RAS in …